Should We Preclude Phase 1 Clinical Trials from Enrolling Elderly Individuals?

Talarico L. , Chen G. , Pazdur R. . Enrollment of elderly patients in clinical trials of cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22(22): 4626–4631.

Lutfullin A. , Kuhlmann J. , Wensing G. . Adverse events in volunteer participating in phase I clinical studies: a single-center 5-year survey in 1,559 subjects. Intern J Clin Pharmacol Ther. 2005; 43(5): 227–236.

Borkowski J.M. , Duerr M. , Donehower R.C. . Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol. 1994; 33(6): 493–496.

van Heeckeren W.J. , Fu P. , Barr P.M. . Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. J Geriatr Oncol. 2011; 2(3): 215–221.

Zafar S.F. , Heilbrun L.K. , Vishnu P. . Participation and survival of geriatric patients in phase I clinical trials: the Karmanos Cancer Institute (KCI) experience. J Geriatr Oncol. 2011; 2(1): 18–24.

Extermann M. , Boler I. , Reich R.R. . Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale in High age patients (CRASH) score. Cancer. 2012; 118(13): 3377–3386.

Hurria A. , Togawa K. , Mohile S.T. . Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29(25): 3457–3465.

Popa M.A. , Wallace K.J. , Brunello A. . Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014; 5(3): 307–314.

Balducci L. , Goetz-Parten D. , Steinman M.A. . Polypharmacy and the management of the older cancer patient. Ann Oncol. 2013; (24 suppl 7): vii36–vii40.

Kelly C.M. , Power D.G. , Lichtman S.M. . Targeted therapy in older patients with solid tumors. J Clin Oncol. 2014; 32(24): 2635–2646.

Korkola J. , Gray J.W. . Breast cancer genome–form and function. Curr Opin Genet D ev. 2010; 20(1): 4–14.

Balducci L. . Studying cancer treatment in the elderly patient population. Cancer Control. 2014; 21(3): 215–220.

Varadhan R. , Yao W. , Matteini A. . Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. J Gerontol A Biol Sci Med Sci. 2014; 69(2): 165–173.

Qu S. , Wen W. , Shu X.O. . Association of leukocyte telomere length and breast cancer risk: nested case-control findings from the Shanghai Women's Health study. Am J Epidemiol. 2013; 177(7): 617–624.

Falandry C. , Bonnefoy M. , Freyer G. . Biology of cancer and aging: a complex association with cellular senescence. J Clin Oncol. 2014; 32(24): 2604–2610.

Luciani A. , Balducci L. . Multiple primary malignancies. Semin Oncol. 2004; 31(2): 264–273.

Denson A.C. , Mahipal A. . Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014; 21(3): 209–214.

Gaddipati H. , Fu P. , Dowlati A. . Phase I clinical trials in patients ≥80. J Geriatr Oncol. 2011; 2(2): 142–146.

Schwandt A. , Harris P.J. , Hunsberger S. . The role of age on dose-limiting toxicities in phase I dose-escalation trials. Clin Cancer Res. 2014; 20(18): 4768–4775.

Nosraty L. , Jylhä M. , Raittila T. . Perceptions of the oldest old on successful aging, Vitality 90+ Study. J Aging Study. 2015; 32: 50–58.